Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions

Robert Coleman, Janet Brown, Evangelos Terpos, Allan Lipton, Matthew R. Smith, Richard Cook, Pierre Major

Research output: Contribution to journalReview article

96 Citations (Scopus)

Abstract

Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.

Original languageEnglish (US)
Pages (from-to)629-639
Number of pages11
JournalCancer Treatment Reviews
Volume34
Issue number7
DOIs
StatePublished - Nov 1 2008

Fingerprint

Bone Diseases
Bone and Bones
Biomarkers
zoledronic acid
Bone Resorption
Neoplasm Metastasis
Direction compound
Integrin-Binding Sialoprotein
RANK Ligand
Diphosphonates
Cytoplasmic and Nuclear Receptors
PubMed
Terminology
Osteogenesis
Neoplasms
Homeostasis
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Coleman, Robert ; Brown, Janet ; Terpos, Evangelos ; Lipton, Allan ; Smith, Matthew R. ; Cook, Richard ; Major, Pierre. / Bone markers and their prognostic value in metastatic bone disease : Clinical evidence and future directions. In: Cancer Treatment Reviews. 2008 ; Vol. 34, No. 7. pp. 629-639.
@article{217101c96e2c48258df3fe8c0bd4df90,
title = "Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions",
abstract = "Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms {"}bone markers{"} or individual bone marker nomenclature, {"}cancer,{"} and {"}metastases.{"} Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.",
author = "Robert Coleman and Janet Brown and Evangelos Terpos and Allan Lipton and Smith, {Matthew R.} and Richard Cook and Pierre Major",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2008.05.001",
language = "English (US)",
volume = "34",
pages = "629--639",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "7",

}

Bone markers and their prognostic value in metastatic bone disease : Clinical evidence and future directions. / Coleman, Robert; Brown, Janet; Terpos, Evangelos; Lipton, Allan; Smith, Matthew R.; Cook, Richard; Major, Pierre.

In: Cancer Treatment Reviews, Vol. 34, No. 7, 01.11.2008, p. 629-639.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bone markers and their prognostic value in metastatic bone disease

T2 - Clinical evidence and future directions

AU - Coleman, Robert

AU - Brown, Janet

AU - Terpos, Evangelos

AU - Lipton, Allan

AU - Smith, Matthew R.

AU - Cook, Richard

AU - Major, Pierre

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.

AB - Background: Bone metastases are prevalent among patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications. Biochemical markers of bone metabolism may meet an unmet need for useful, noninvasive, and sensitive surrogate information for following patients' skeletal health. Materials and methods: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases." Abstracts and reports from meetings were included only when they related directly to previously published work. Only papers published in English between 1990 and 2007 were included. Results: Recent retrospective analyses with bisphosphonates, and particularly with zoledronic acid, have shown significant correlations between biochemical markers of bone metabolism levels and clinical outcomes, especially for bone resorption markers. Clinical results for biochemical markers of bone formation and resorption and other emerging markers of bone metabolism including bone sialoprotein, receptor-activator of nuclear factor-κB ligand, osteoprotegerin, and other markers are presented. However, biochemical markers of bone metabolism are not yet an established surrogate endpoint for treatment efficacy. Conclusions: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy. Prospective randomized clinical trials are underway to further assess the utility of markers of bone metabolism in patients with bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=53649083433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649083433&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2008.05.001

DO - 10.1016/j.ctrv.2008.05.001

M3 - Review article

C2 - 18579314

AN - SCOPUS:53649083433

VL - 34

SP - 629

EP - 639

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 7

ER -